Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis

Background: Tacrolimus (TAC) is used for the management of ulcerative colitis (UC). However, there are few reports on the effectiveness of its long-term administration. TAC is also known to cause renal toxicity. The aim of this study was to evaluate long-term effectiveness and monitor changes in renal function during prolonged TAC use in patients with UC. Methods: Medical records of 50 UC patients treated with TAC were retrospectively reviewed. Clinical outcomes were assessed at 6, 12, 24, and 36 months after initiating TAC. We also monitored chronological changes in renal function. Results: Thirty-nine patients were treated with TAC for more than 3 months. Relapse-free survival among these patients at 6, 12, 24, and 36 months was 82%, 69%, 41%, and 23%, respectively. On the other hand, renal function was reduced in 35.9% of patients. We found that irreversible renal dysfunction was more likely to occur in cases in which the estimated glomerular-filtration rate (eGFR) was reduced by more than 30%. Conclusion: This study demonstrated the potential use of TAC as an effective option in the long-term medical management of UC, although it tended to increase the risk of nephrotoxicity. There is a need for the careful monitoring of renal function during TAC administration.

[1]  A. Kronbichler,et al.  Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. , 2019, Autoimmunity reviews.

[2]  R. González‐Grande,et al.  Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis , 2017 .

[3]  B. Feagan,et al.  Histologic scoring indices for evaluation of disease activity in ulcerative colitis. , 2017, The Cochrane database of systematic reviews.

[4]  S. Ito,et al.  Prolonged tacrolimus for pediatric gastrointestinal disorder: Double‐edged sword? , 2017, Pediatrics international : official journal of the Japan Pediatric Society.

[5]  J. Cotter,et al.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review , 2017, Drugs.

[6]  B. Iizuka,et al.  Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study , 2016, Gastroenterology research and practice.

[7]  T. Shimosegawa,et al.  A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis , 2016, Gastroenterology research and practice.

[8]  R. Gearry,et al.  New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis. , 2015, The New Zealand medical journal.

[9]  K. Ohtsuka,et al.  Tacrolimus for the Treatment of Ulcerative Colitis , 2015, Intestinal research.

[10]  H. Hanai,et al.  Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  K. Higuchi,et al.  Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. , 2015, World journal of gastroenterology.

[12]  R. Khosla,et al.  Cyclosporine in steroid refractory acute severe colitis. , 2014, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.

[13]  H. Ogata,et al.  Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. , 2013, Journal of Crohn's & colitis.

[14]  S. Ng,et al.  Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres. , 2013, Journal of Crohn's & colitis.

[15]  A. Kukla,et al.  Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence , 2013, American Journal of Nephrology.

[16]  H. Miwa,et al.  Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA , 2013, BMC Gastroenterology.

[17]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[18]  G. Rogler,et al.  First-Line Therapies in Inflammatory Bowel Disease , 2012, Digestion.

[19]  T. Matsui,et al.  Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis , 2012, Inflammatory bowel diseases.

[20]  D. Altman,et al.  Translational Gastroenterology , 2011 .

[21]  T. Chiba,et al.  Tacrolimus Therapy as an Alternative to Thiopurines for Maintaining Remission in Patients With Refractory Ulcerative Colitis , 2011, Journal of clinical gastroenterology.

[22]  F. Lehner,et al.  Biopsy‐Diagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  B. Wiedenmann,et al.  Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease—A Long-Term Follow-Up , 2006, The American Journal of Gastroenterology.

[24]  T. Matsui,et al.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.

[25]  B. Fellström.  Cyclosporine nephrotoxicity. , 2004, Transplantation proceedings.

[26]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[27]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[28]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[29]  K. Fellermann,et al.  Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506) , 1998, American Journal of Gastroenterology.

[30]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[31]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[32]  T. Starzl,et al.  FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION , 1989, The Lancet.

[33]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[34]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987, The Journal of antibiotics.

[35]  Z. Ran,et al.  Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. , 2019, Inflammatory bowel diseases.

[36]  B. Feagan,et al.  Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. , 2018, The Cochrane database of systematic reviews.

[37]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[38]  Víctor Amo Trillo,et al.  Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis. , 2017, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[39]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. , 1987, The Journal of antibiotics.